Bayer's US Push Meets a Wall of Legal Risk as JPMorgan Cools on Q3 Hopes

Bayer shares slid 10% in a week as a new Roundup trial opened in Missouri and JPMorgan flagged high Q3 expectations, testing its $2.2B Ohio bet.

Bayer is betting big on America — but Wall Street wants proof before it buys the story. With a fresh trial over its Roundup herbicide underway in Missouri and a cautious note from JPMorgan setting the tone, the German group's ambitious US expansion is colliding with a legal and financial reality check that has knocked 10% off its share price in a single week.

The stock closed Friday at EUR 45.02. That weekly slide sits awkwardly against a year-to-date gain of 22%, a reminder that Bayer's medium-term recovery remains intact even as near-term nerves flare. The tension is easy to explain: the company is pouring money into the world's largest healthcare market while still fighting fires from its past.

JPMorgan Stays Bullish, But Not on Q3

Analyst Richard Vosser kept his "Overweight" rating and a EUR 61 price target on Wednesday, yet flagged a problem with timing. Early market expectations for the third quarter may be set too high, he warned, pointing to calendar-related effects in the agricultural division as the chief culprit. It is a subtle caution rather than a downgrade, but it lands at a moment when investors are already jittery.

The legal front is doing little to calm them. In Missouri, a new Roundup trial has opened, with three female plaintiffs alleging the company failed to adequately test the herbicide. The case falls outside the proposed collective settlement and is proceeding despite a US Supreme Court ruling on warning labels. Bayer rejects the allegations. Separately, a court roughly a week ago declined to dismiss patent litigation tied to mRNA technology.

Those courtroom battles have become the dominant source of uncertainty for shareholders, overshadowing the operational story Bayer is trying to tell.

A $2.2 Billion Anchor in Ohio

That story is largely about manufacturing. Bayer plans to build a pharmaceutical production site in New Albany, Ohio, backed by a $2.2 billion investment. The facility is designed to add capacity for active ingredients and finished medicines in oncology as well as cardiovascular and kidney care, and it is expected to generate around 600 permanent jobs alongside roughly 1,500 positions during construction.

The timeline is long. The active-ingredient module is slated to come online in 2031, with finished-drug production following in 2034. The project forms part of a broader commitment: more than $7 billion has already flowed into US research, development and production over the past five years.

The strategic logic is straightforward. The US already accounts for 35% of Bayer's total pharmaceutical revenue, up from 20% in 2018, and the company aims to double its US medicine sales by 2030. Local production also insulates the group from protectionist shifts in Washington, shortening the distance to clinical partners and sales channels alike.

Financing the Ambition

None of this comes cheap, and Bayer is reshuffling its balance sheet to keep pace. The company placed EUR 2 billion in hybrid bonds on the capital markets. It also offloaded the cancer drug Stivarga, with rights going to Grünenthal for up to EUR 375 million. In a smaller personnel move, Dr. Christoph Koenen stepped into the role of Chief Medical Officer for the pharmaceutical division.

For shareholders, the calculus is a delicate one. The accelerated US build-out secures access to high-margin business, but the billions in spending add pressure to free cash flow at a time when management is still working through legacy financial burdens.

November 3 Is the Real Test

Hard numbers arrive on November 3, 2026, when Bayer publishes its quarterly statement for the third quarter. Only then will investors learn whether the agricultural division's drag is as pronounced as JPMorgan suspects — and whether the cautious mood gripping the stock is justified or simply a case of nerves running ahead of the facts.